ResearcherJahrom University of Medical SciencesNo recent work listed
Masumeh Sanaei
Matched on ORCID iD 0000-0002-7813-4864; OpenAlex author ID A5112569136.
Their work
- Papers
- 5 (first author 4, last author 0)
- Trials
- 0
- Grants
- 0
- Collaborators
- 3
2020: 1 paper · 2021: 2 papers · 2022: 2 papers
Papers 5
- Effect of Sodium Butyrate on p16INK4a, p14ARF, p15INK4b, Class I HDACs (HDACs 1, 2, 3) Class II HDACs (HDACs 4, 5, 6), Cell Growth Inhibition and Apoptosis Ind… First author DOI 10.31557/apjcp.2022.23.3.795↗
- Effect of Sodium Butyrate and Epigallocatechin-3-Gallate on the Genes Expression of Intrinsic Apoptotic Pathway on PA-TU-8902, CFPAC-1, and CAPAN-1 Human Pancr… Co-author DOI 10.31661/gmj.v11i.2248↗
- Effect of Zebularine in Comparison to Trichostatin A on the Intrinsic and Extrinsic Apoptotic Pathway, Cell Viability, and Apoptosis in Hepatocellular Carcinom… First author DOI 10.22037/ijpr.2021.115097.15196↗
- Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma. First author DOI 10.4103/1735-5362.314824↗
- Effect of Zebularine on p16INK4a, p14ARF, p15INK4b, and DNA Methyltransferase 1 Gene Expression, Cell Growth Inhibition, and Apoptosis Induction in Human Hepat… First author DOI 10.22037/ijpr.2020.112223.13614↗
Closest collaborators
The 3 strongest of 3 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Fraidoon Kavoosi · 5 shared papers, 2020–2022
- Paper Effect of Sodium Butyrate on p16INK4a, p14ARF, p15INK4b, Class I HDACs (HDACs 1, 2, 3) Class II HDACs (HDACs 4, 5, 6), … DOI 10.31557/apjcp.2022.23.3.795↗
- Paper Effect of Zebularine in Comparison to Trichostatin A on the Intrinsic and Extrinsic Apoptotic Pathway, Cell Viability, … DOI 10.22037/ijpr.2021.115097.15196↗
- Paper Effect of vorinostat on INK4 family and HDACs 1, 2, and 3 in pancreatic cancer and hepatocellular carcinoma. DOI 10.4103/1735-5362.314824↗
- Iraj Poursadgh Soufiani · 1 shared paper, 2022
- Farzane Hosseini · 1 shared paper, 2020
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.